论文部分内容阅读
不能切除肝癌过去罕见有获得根治者。近年肝癌的缩小后切除为不能切除肝癌提供了根治的希望,但关键是如何使肝癌缩小。实践表明,亲肿瘤抗体导向治疗是一种能大量杀伤肿瘤的方法,国际上仍在不断深入。但由于肿瘤与机体内的复杂环境等因素,其单一应用难以完全消灭肿瘤,而导向综合治疗则是一个方向。“七五”攻关已证实亲肝癌抗体导向综合治疗有助部分不能切除肝癌的缩小后切除,其远期疗效使人鼓舞,但仍需进一步提高。本成果总结了1991～1995年间有关亲肝癌抗体的临床规律和双功能与基因工程抗体的研究。
Unresectable liver cancer in the past have received radical cure. In recent years, the reduction of liver cancer after resection of the liver can not be removed to provide a radical hope, but the key is how to make liver cancer reduced. Practice shows that the pro-tumor antibody-directed therapy is a way to kill a large number of tumors, the international community is still in-depth. However, due to the complex environment in the tumor and the body and other factors, its single application is difficult to completely eliminate the tumor, and the integrated treatment is one direction. “Seventh Five-Year” research has confirmed that the pro-liver cancer antibody-directed comprehensive treatment can help partially resectable resection of liver cancer, its long-term effect is encouraging, but still need further improvement. This result summarizes the 1991 to 1995 clinical patterns of antibodies against hepatocellular carcinoma and bifunctional and genetic engineering antibodies.